Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429057 | 0.91 | ALK (0.48) | TLR9TLR7TLR8LRRK2ALK | |
| SCHEMBL13429309 | 0.90 | TLR9 (0.44) | TLR9TLR7TLR8LRRK2ABL1 | |
| SCHEMBL13429021 | 0.89 | TNKS (0.52) | TLR9TLR7TLR8ALKTNKS | |
| SCHEMBL3225576 | 0.82 | KIF11 (0.47) | TLR9TLR7TLR8KDM4E | |
| SCHEMBL13429184 | 0.78 | GRIN2D (0.45) | KDM4E | |
| SCHEMBL13429268 | 0.78 | TLR9 (0.47) | TLR9TLR7TLR8METAP2 | |
| SCHEMBL13429163 | 0.78 | AXL (0.41) | METAP2 | |
| SCHEMBL13429235 | 0.77 | CNR2 (0.51) | TLR7TLR8 | |
| SCHEMBL13429161 | 0.77 | HPGD (0.54) | KDM4E | |
| SCHEMBL13429015 | 0.76 | SMN1; SMN2 (0.54) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | TLR9 1426/4885TLR7 1399/4885TLR8 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.